Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice

This study was conducted to investigate the real‐world effectiveness and tolerability of rituximab‐containing chemoimmunotherapies, which have become the standard of care for chronic lymphocytic leukaemia (CLL), particularly for physically fit patients. Furthermore, current treatment patterns in clinical practice were documented, and an unselected real‐life population was compared with older, comorbid patients.

[1]  W. Hiddemann,et al.  Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study , 2018, Haematologica.

[2]  W. Klapper,et al.  First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. , 2016, The Lancet. Oncology.

[3]  C. Fegan,et al.  Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study , 2015, Leukemia.

[4]  W. Knauf,et al.  Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective Tumour Registry Lymphatic Neoplasms† , 2014, Hematological oncology.

[5]  E. Montserrat,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Gribben,et al.  Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[8]  M. Griffin,et al.  Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials , 2013, Expert opinion on biological therapy.

[9]  E. Kimby,et al.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Döhner,et al.  Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Döhner,et al.  Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Montserrat,et al.  Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[14]  J. Gribben.  Chronic lymphocytic leukemia: planning for an aging population , 2010, Expert review of anticancer therapy.

[15]  P. Ganly,et al.  Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Hallek,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  D. Catovsky,et al.  Disease burden of chronic lymphocytic leukaemia within the European Union , 2008, European journal of haematology.

[18]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[19]  G. Jenkins,et al.  Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia , 2008, Leukemia & lymphoma.